General Information
We are a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material. Our Core Products include the CanGaroo, the first and only natural biologic envelope designed to help reduce complications with CIED implants (pacemakers and defibrillators); FiberCel Fiber Viable Bone Matrix, ViBone and OsteGro V for spine and orthopedic procedures; SimpliDerm, a pre-hydrated human acellular dermal matrix for soft tissue repair, and a portfolio of extracellular matrices for use in vascular and cardiac repair (ProxiCor, Tyke and VasCure). Our proprietary products are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair and soft tissue reconstruction markets, which represented a combined $3 billion market opportunity in the United States in 2019. To expand our commercial reach, we have commercial relationships with major medical device companies, such as Boston Scientific and Medtronic, to promote and sell some of our Core Products.
We estimate that more than 2 million patients were either implanted with medical devices, such as pacemakers, defibrillators, neuro-stimulators, spinal fusion and trauma fracture hardware or tissue expanders for breast reconstruction, in the United States in 2019.
Employees: 151
Founded: 2015
Contact Information
Address 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904
Phone Number (240) 247-1170
Web Address
View Prospectus: AZIYO BIOLOGICS, INC.
Financial Information
Market Cap $133.1mil
Revenues $23.2 mil (last 12 months)
Net Income $-15.6 mil (last 12 months)
IPO Profile
Symbol AZYO
Exchange NASDAQ
Shares (millions): 2.9
Price range $17.00 - $17.00
Est. $ Volume $50.0 mil
Manager / Joint Managers Piper Sandler/ Cowen and Company
CO-Managers Cantor Fitzgerald/ Truist Securities
Expected To Trade: 10/8/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change